Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Up 2,234.2% in December

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 33,566 shares, a growth of 2,234.2% from the December 15th total of 1,438 shares. Based on an average trading volume of 4,881 shares, the days-to-cover ratio is currently 6.9 days. Approximately 22.4% of the company’s stock are sold short. Approximately 22.4% of the company’s stock are sold short. Based on an average trading volume of 4,881 shares, the days-to-cover ratio is currently 6.9 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC lifted its holdings in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,891 shares of the company’s stock after acquiring an additional 1,215 shares during the period. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

Amplify Weight Loss Drug & Treatment ETF Trading Down 0.8%

Shares of NYSEARCA:THNR opened at $25.98 on Wednesday. Amplify Weight Loss Drug & Treatment ETF has a 52 week low of $18.56 and a 52 week high of $26.44. The company’s 50 day moving average is $25.33 and its two-hundred day moving average is $23.94. The company has a market cap of $3.90 million, a PE ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The firm also recently announced an annual dividend, which was paid on Wednesday, December 31st. Investors of record on Tuesday, December 30th were issued a $0.4132 dividend. This represents a yield of 162.0%. The ex-dividend date of this dividend was Tuesday, December 30th.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.